Mitochondria as a target in treatment

Environmental and Molecular Mutagenesis

Volumn 51, Issue 5, 2010, Pages 462-475

  Frantz, Marie Céline ^a   Wipf, Peter ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Gramicidin S; Mitochondria targeted antioxidant; Nitroxide; Oxidative stress; Reactive oxygen species; TEMPO

Indexed keywords

2 METHOXYESTRADIOL; 7 CHLORO 5 (2 CHLOROPHENYL) 1,5 DIHYDRO 4,1 BENZOTHIAZEPIN 2(3H) ONE; ANTHRACYCLINE DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARIAMYCIN; ARSENIC TRIOXIDE; BENZODIAZEPINE; CATENA; DAUNORUBICIN; DIAZOXIDE; DODECYLTRIPHENYLPHOSPHONIUM BROMIDE; DOXORUBICIN; ELESCLOMOL; GADOLINIUM TEXAPHYRIN; GLIBENCLAMIDE; GRAMICIDIN; IDEBENONE; IMEXON; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); MITOQ; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NUCLEOSIDE DERIVATIVE; PACLITAXEL; PHOSPHOLIPID; REACTIVE OXYGEN METABOLITE; RO 54864; SS 02; SS 20; SS 31; SULFONYLUREA DERIVATIVE; SULOFENUR; TETRAPEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XJB 5131;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CATALYSIS; CELL DEATH; CELL FUNCTION; CELL ORGANELLE; CELL SURVIVAL; CLINICAL TRIAL; CONJUGATE; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; HUMAN; INSULIN RELEASE; LEBER HEREDITARY OPTIC NEUROPATHY; LIPID PEROXIDATION; LIVER INJURY; LUNG CANCER; MELANOMA; METABOLIC DISORDER; METASTASIS; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OXIDATIVE STRESS; PANCREAS CANCER; PARKINSON DISEASE; PROMYELOCYTIC LEUKEMIA; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ACETYLCYSTEINE; ANTIOXIDANTS; BENZODIAZEPINES; GLUTATHIONE; GRAMICIDIN; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; PRODRUGS; REACTIVE OXYGEN SPECIES; SULFONYLUREA COMPOUNDS;

EID: 77953508445     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20554     Document Type: Review

References (112)

1. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RAJ, Murphy MP, Sammut IA. 2005. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19:1088-1095.
2. Armstrong JS. 2007. Mitochondrial medicine: Pharmacological targeting of mitochondria in disease. Br J Pharmacol 151:1154-1165.
3. Asayama S, Kawamura E, Nagaoka S, Kawakami H. 2006. Design of manganese porphyrin modified with mitochondrial signal peptide for a new antioxidant. Mol Pharm 3:468-470.
4. Balaban RS, Nemoto S, Finkel T. 2005. Mitochondria, oxidants, and aging. Cell 120:483-495.
5. Bayir H, Fadeel B, Palladino MJ, Witasp E, Kurnikov IV, Tyurina YY, Tyurin VA, Amoscato AA, Jiang J, Kochanek PM, DeKosky ST, Greenberger JS, Shvedova AA, Kagan VE. 2006. Apoptotic interactions of cytochrome c: Redox flirting with anionic phospholipids within and outside of mitochondria. Biochim Biophys Acta Bioenerg 1757:648-659.
6. Belikova NA, Jiang J, Stoyanovsky DA, Glumac A, Bayir H, Greenberger JS, Kagan VE. 2009. Mitochondria-targeted (2-hydroxyamino-vinyl)-triphenyl- phosphonium releases NO· and protects mouse embryonic cells against irradiation-induced apoptosis. FEBS Lett 583:1945-1950.
7. Borisenko GG, Kapralov AA, Tyurin VA, Maeda A, Stoyanovsky DA, Kagan VE. 2008. Molecular design of new inhibitors of peroxidase activity of cytochrome c/cardiolipin complexes: Fluorescent oxadiazole-derivatized cardiolipin. Biochemistry 47:13699-13710.
8. Carney DA. 2008. Arsenic trioxide mechanisms of action - Looking beyond acute promyelocytic leukemia. Leuk Lymphoma 49:1846-1851.
9. Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, Rizzuto R. 2009. Mitochondria, calcium and cell death: A deadly triad in neurodegeneration. Biochim Biophys Acta Bioenerg 1787:335-344.
10. Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, Hong MK. 2007a. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coronary Artery Dis 18:215-220.
11. Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. 2007b. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem 282:4634-4642.
12. Dessolin J, Schuler M, Quinart A, de Giorgi F, Ghosez L, Ichas F. 2002. Selective targeting of synthetic antioxidants to mitochondria: Towards a mitochondrial medicine for neurodegenerative diseases? Eur J Pharmacol 447:155-161.
13. Dhanasekaran A, Kotamraju S, Karunakaran C, Kalivendi SV, Thomas S, Joseph J, Kalyanaraman B. 2005. Mitochondria superoxide dismutase mimetic inhibits peroxide-induced oxidative damage and apoptosis: Role of mitochondrial superoxide. Free Radical Biol Med 39:567-583.
14. Di Lisa F, Kaludercic N, Carpi A, Menabo R, Giorgio M. 2009. Mitochondria and vascular pathology. Pharmacol Rep 61:123-130.
15. Dirnagl U, Iadecola C, Moskowitz MA. 1999. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 22:391-397.
16. Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow H-HS, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R. 2007. Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 25:1779-1784.
17. Dykens JA, Will Y. 2007. The significance of mitochondrial toxicity testing in drug development. Drug Discov Today 12:777-785. (Pubitemid 47362789)
18. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Del Rio G, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R. 1999. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-1038.
19. Engel RH, Evens AM. 2006. Oxidative stress and apoptosis: A new treatment paradigm in cancer. Front Biosci 11:300-312.
20. Filipovska A, Kelso GF, Brown SE, Beer SM, Smith RAJ, Murphy MP. 2005. Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic: Insights into the interaction of Ebselen with mitochondria. J Biol Chem 280:24113-24126.
21. Fink MP, Macias CA, Xiao J, Tyurina YY, Delude RL, Greenberger JS, Kagan VE, Wipf P. 2007a. Hemigramicidin-TEMPO conjugates: Novel mitochondria-targeted antioxidants. Crit Care Med 35:S461-S467. (Pubitemid 47312180)
22. Fink MP, Macias CA, Xiao J, Tyurina YY, Jiang J, Belikova N, Delude RL, Greenberger JS, Kagan VE, Wipf P. 2007b. Hemigramicidin-TEMPO conjugates: Novel mitochondria-targeted anti-oxidants. Biochem Pharmacol 74:801-809. (Pubitemid 47212072)
23. Friederich M, Hansell P, Palm F. 2009. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev 5:120-144.
24. Fruehauf JP, Meyskens FL Jr. 2007. Reactive oxygen species: A breath of life or death? Clin Cancer Res 13:789-794.
25. Galiegue S, Tinel N, Casellas P. 2003. The peripheral benzodiazepine receptor: A promising therapeutic drug target. Curr Med Chem 10:1563-1572. (Pubitemid 36896557)
26. Gelderman KA, Hultqvist M, Olsson LM, Bauer K, Pizzolla A, Olofsson P, Holmdahl R. 2007. Rheumatoid arthritis: The role of reactive oxygen species in disease development and therapeutic strategies. Antioxid Redox Signal 9:1541-1567.
27. Gogvadze V, Orrenius S, Zhivotovsky B. 2009. Mitochondria as targets for chemotherapy. Apoptosis 14:624-640.
28. Goldstein S, Merenyi G, Russo A, Samuni A. 2003. The role of oxoammonium cation in the SOD-mimic activity of cyclic nitroxides. J Am Chem Soc 125:789-795.
29. Gottlieb E. 2009. Cancer: The fat and the furious. Nature 461:44-45.
30. 2+ signaling: Old guests, new functions. Pflügers Archiv Eur J Physiol 455:375-396.
31. Green DR, Kroemer G. 2004. The pathophysiology of mitochondrial cell death. Science 305:626-629.
32. Hamanaka RB, Chandel NS. 2009. Mitochondrial reactive oxygen species regulate hypoxic signaling. Curr Opin Cell Biol 21:894-899.
33. Horobin RW, Trapp S, Weissig V. 2007. Mitochondriotropics: A review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria. J Controlled Release 121:125-136.
34. Horton KL, Kelley SO. 2009. Engineered apoptosis-inducing peptides with enhanced mitochondrial localization and potency. J Med Chem 52:3293-3299.
35. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. 2008. Mitochondria-penetrating peptides. Chem Biol 15:375-382.
36. Hoye AT, Davoren JE, Wipf P, Fink MP, Kagan VE. 2008. Targeting mitochondria. Acc Chem Res 41:87-97.
37. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. 2000. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390-395.
38. Jauslin ML, Meier T, Smith RAJ, Murphy MP. 2003. Mitochondriatargeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 17:1972-1974.
39. Jiang J, Kurnikov I, Belikova NA, Xiao J, Zhao Q, Amoscato AA, Braslau R, Studer A, Fink MP, Greenberger JS, Wipf P, Kagan VE. 2007. Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther 320:1050-1060.
40. Jiang J, Belikova NA, Hoye AT, Zhao Q, Epperly MW, Greenberger JS, Wipf P, Kagan VE. 2008. A mitochondria-targeted nitroxide/hemigramicidin S conjugate protects mouse embryonic cells against gamma irradiation. Int J Radiat Oncol Biol Phys 70:816-825.
41. Jiang J, Stoyanovsky DA, Belikova NA, Tyurina YY, Zhao Q, Tungekar MA, Kapralova V, Huang Z, Mintz AH, Greenberger JS, Kagan VE. A mitochondria- targeted triphenylphosphonium-conjugated nitrooxide functions as a radioprotector/mitigator. Radiat Res (in press).
42. Jung K, Reszka R. 2001. Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev 49:87-105.
43. Kagan VE, Bayir A, Bayir H, Stoyanovsky D, Borisenko GG, Tyurina YY, Wipf P, Atkinson J, Greenberger JS, Chapkin RS, Belikova NA. 2009a. Mitochondria-targeted disruptors and inhibitors of cytochrome c/cardiolipin peroxidase complexes: A new strategy in anti-apoptotic drug discovery. Mol Nutr Food Res 53:104-114.
44. Kagan VE, Bayir HA, Belikova NA, Kapralov O, Tyurina YY, Tyurin VA, Jiang J, Stoyanovsky DA, Wipf P, Kochanek PM, Greenberger JS, Pitt B, Shvedova AA, Borisenko G. 2009b. Cytochrome c/cardiolipin relations in mitochondria: A kiss of death. Free Radical Biol Med 46:1439-1453.
45. Kagan VE, Wipf P, Stoyanovsky D, Greenberger JS, Borisenko G, Belikova NA, Yanamala N, Samhan Arias AK, Tungekar MA, Jiang J, Tyurina YY, Ji J, Klein-Seetharaman J, Pitt BR, Shvedova AA, Bayir H. 2009c. Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions. Adv Drug Deliv Rev 61:1375-1385.
46. Kanai A, Zabbarova I, Amoscato A, Epperly M, Xiao J, Wipf P. 2007. Mitochondrial targeting of radioprotectants using peptidyl conjugates. Org Biomol Chem 5:307-309.
47. Kaufmann P, Thompson JLP, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B. 2009. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 66:235-244.
48. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RAJ, Murphy MP. 2001. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J Biol Chem 276:4588-4596.
49. Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang C-Y, Zhang M, Du Z, Barsoum J, Bertin J. 2008. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7:2319-2327.
50. Ko YT, Falcao C, Torchilin VP. 2009. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)2 and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 6:971-977.
51. Koene S, Smeitink J. 2009. Mitochondrial medicine: Entering the era of treatment. J Intern Med 265:193-209.
52. Krishna MC, Samuni A, Taira J, Goldstein S, Mitchell JB, Russo A. 1996. Stimulation by nitroxides of catalase-like activity of hemeproteins: Kinetics and mechanism. J Biol Chem 271:26018-26025.
53. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, Morrow JD, van Remmen H, Sedivy JM, Yamasoba T, Tanokura M, Weindruch R, Leeuwenburgh C, Prolla TA. 2005. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309:481-484.
54. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. 2001. Mitochondrial dysfunction in cardiac disease: Ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol 33:1065-1089.
55. Lu B. 2009. Mitochondrial dynamics and neurodegeneration. Curr Neurol Neurosci Rep 9:212-219.
56. Macias CA, Chiao JW, Xiao J, Arora DS, Tyurina YY, Delude RL, Wipf P, Kagan VE, Fink MP. 2007. Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock. Ann Surg 245:305-314.
57. Mattson MP, Kroemer G. 2003. Mitochondria in cell death: Novel targets for neuroprotection and cardioprotection. Trends Mol Med 9:196-205.
58. McBride HM, Neuspiel M, Wasiak S. 2006. Mitochondria: More than just a powerhouse. Curr Biol 16:R551-R560.
59. Meier T, Buyse G. 2009. Idebenone: An emerging therapy for Friedreich ataxia. J Neurol 256:25-30.
60. Mitchell JB, Russo A, Kuppusamy P, Krishna MC. 2000. Radiation, radicals, and images. Ann NY Acad Sci 899:28-43.
61. Mizuguchi Y, Chen J, Seshan SV, Poppas DP, Szeto HH, Felsen D. 2008. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol 295:F1545-F1553.
62. Murphy MP. 1997. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol 15:326-330.
63. Murphy MP. 2009. How mitochondria produce reactive oxygen species. Biochem J 417:1-13.
64. Murphy MP, Smith RAJ. 2007. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47:629-656.
65. Murphy MP, Echtay KS, Blaikie FH, Asin-Cayuela J, Cochemé HM, Green K, Buckingham JA, Taylor ER, Hurrell F, Hughes G, Miwa S, Cooper CE, Svistunenko DA, Smith RAJ, Brand MD. 2003. Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: Studies using a mitochondria-targeted spin trap derived from a-phenyl-Ntert-butylnitrone. J Biol Chem 278:48534-48545.
66. Neuzil J, Dong L-F, Ramanathapuram L, Hahn T, Chladova M, Wang X-F, Zobalova R, Prochazka L, Gold M, Freeman R, Turanek J, Akporiaye ET, Dyason JC, Ralph SJ. 2007. Vitamin E analogues as a novel group of mitocans: Anti-cancer agents that act by targeting mitochondria. Mol Aspects Med 28:607-645.
67. Pearce LL, Epperly MW, Greenberger JS, Pitt BR, Peterson J. 2001. Identification of respiratory complexes I, III as mitochondrial sites of damage following exposure to ionizing radiation and nitric oxide. Nitric Oxide 5:128-136.
68. Pei Y, Lilly MJ, Owen DJ, D'souza LJ, Tang X-Q, Yu J, Nazarbaghi R, Hunter A, Anderson CM, Glasco S, Ede NJ, James IW, Maitra U, Chandrasekaran S, Moos WH, Ghosh SS. 2003. Efficient syntheses of benzothiazepines as antagonists for the mitochondrial sodium-calcium exchanger: Potential therapeutics for type II diabetes. J Org Chem 68:92-103.
69. Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. 2007. Coenzyme Q10 in cardiovascular disease. Mitochondrion 7:S154-S167.
70. Pérez VI, Bokov A, Remmen HV, Mele J, Ran Q, Ikeno Y, Richardson A. 2009. Is the oxidative stress theory of aging dead? Biochim Biophys Acta 1790:1005-1014.
71. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF. 2006. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98:1141-1148.
72. Pompella A, Visvikis A, Paolicchi A, de Tata V, Casini AF. 2003. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 66:1499-1503.
73. Prenner EJ, Lewis RNAH, McElhaney RN. 1999. The interaction of the antimicrobial peptide gramicidin S with lipid bilayer model and biological membranes. Biochim Biophys Acta Biomembr 1462:201-221.
74. Rajagopalan MS, Gupta K, Epperly MW, Franicola D, Zhang X, Wang H, Zhao H, Tyurin VA, Pierce JG, Kagan VE, Wipf P, Kanai AJ, Greenberger JS. 2009. The mitochondria-targeted nitroxide JP4-039 augments potentially lethal irradiation damage repair. In Vivo 23:717-726.
75. Reddy PH. 2008. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromol Med 10:291-315.
76. Reeve AK, Krishnan KJ, Turnbull D. 2008a. Mitochondrial DNA mutations in disease, aging, and neurodegeneration. Ann NY Acad Sci 1147:21-29.
77. Reeve AK, Krishnan KJ, Turnbull DM. 2008b. Age related mitochondrial degenerative disorders in humans. Biotechnol J 3:750-756.
78. Richards GM, Mehta MP. 2007. Motexafin gadolinium in the treatment of brain metastases. Exp Opin Pharmacother 8:351-359.
79. Rogge MM. 2009. The role of impaired mitochondrial lipid oxidation in obesity. Biol Res Nurs 10:356-373.
80. Samuni A, Goldstein S, Russo A, Mitchell JB, Krishna MC, Neta P. 2002. Kinetics and mechanism of hydroxyl radical and OHadduct radical reactions with nitroxides and with their hydroxylamines. J Am Chem Soc 124:8719-8724.
81. Schlüter T, Struy H, Schönfeld P. 2000. Protection of mitochondrial integrity from oxidative stress by the triaminopyridine derivative flupirtine. FEBS Lett 481:42-46.
82. Schulz JB, Di Prospero NA, Fischbeck K. 2009. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol 256:42-45.
83. Sheu S-S, Nauduri D, Anders MW. 2006. Targeting antioxidants to mitochondria: A new therapeutic direction. Biochim Biophys Acta Mol Basis Dis 1762:256-265.
84. Smith RAJ, Porteous CM, Coulter CV, Murphy MP. 1999. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 263:709-716.
85. Song W, Shin J, Lee J, Kim H, Oh D, Edelberg JM, Wong SC, Szeto H, Hong MK. 2005. A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats. Coronary Artery Dis 16:407-410.
86. Soule BP, Hyodo F, Matsumoto K-I, Simone NL, Cook JA, Krishna MC, Mitchell JB. 2007. The chemistry and biology of nitroxide compounds. Free Radical Biol Med 42:1632-1650.
87. Starkov AA. 2008. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann NY Acad Sci 1147:37-52.
88. Stoyanovsky DA, Vlasova II, Belikova NA, Kapralov A, Tyurin V, Greenberger JS, Kagan VE. 2008. Activation of NO donors in mitochondria: Peroxidase metabolism of (2-hydroxyamino-vinyl)-triphenyl-phosphonium by cytochrome c releases NO, protects cells against apoptosis. FEBS Lett 582:725-728.
89. Sutherland TE, Anderson RL, Hughes RA, Altmann E, Schuliga M, Ziogas J, Stewart AG. 2007. 2-Methoxyestradiol - A unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discov Today 12:577-584.
90. Szeto HH. 2006. Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents. APPS J 8:E521-E531.
91. Szeto HH. 2008. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal 10:601-620.
92. + channel openers? Trends Pharmacol Sci 20:157-161.
93. Szewczyk A, Wojtczak L. 2002. Mitochondria as a pharmacological target. Pharmacol Rev 54:101-127.
94. Szewczyk A, Jarmuszkiewicz W, Kunz WS. 2009. Mitochondrial potassium channels. IUBMB Life 61:134-143.
95. Tauskela J. 2007. MitoQ - A mitochondria-targeted antioxidant. IDrugs 10:399-412.
96. Thomas DA, Stauffer C, Zhao K, Yang H, Sharma VK, Szeto HH, Suthanthiran M. 2007. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttrans-plantation function. J Am Soc Nephrol 18:213-222.
97. Todesco L, Waldhauser K, Krähenbühl S. 2006. Mitochondrial toxicity of drugs. Chimia 60:37-39.
98. Toogood PL. 2008. Mitochondrial drugs. Curr Opin Chem Biol 12:457-463.
99. Trachootham D, Alexandre J, Huang P. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8:579-591.
100. Turner N, Heilbronn LK. 2008. Is mitochondrial dysfunction a cause of insulin resistance? Trends Endocrinol Metab 19:324-330.
101. Veenman L, Gavish M. 2006. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol Ther 110:503-524.
102. 2+ handling in human complex I deficiency. J Biol Chem 279:40328-40336.
103. Wasilewski M, Scorrano L. 2009. The changing shape of mitochondrial apoptosis. Trends Endocrinol Metab 20:287-294.
104. Winterbourn CC, Parsons-Mair HN, Gebicki S, Gebicki JM, Davies MJ. 2004. Requirements for superoxide-dependent tyrosine hydroperoxide formation in peptides. Biochem J 381:241-248.
105. Wipf P, Xiao J, Jiang J, Belikova NA, Tyurin VA, Fink MP, Kagan VE. 2005. Mitochondrial targeting of selective electron scavengers: Synthesis and biological analysis of hemigramicidin-TEMPO conjugates. J Am Chem Soc 127:12460-12461.
106. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. 2009. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Antioxid Redox Signal 11:2095-2104.
107. Yousif LF, Stewart KM, Kelley SO. 2009. Targeting mitochondria with organelle-specific compounds: Strategies and applications. Chem-BioChem 10:1939-1950.
108. Zhang R, Goldstein S, Samuni A. 1999. Kinetics of superoxide-induced exchange among nitroxide antioxidants and their oxidized and reduced forms. Free Radical Biol Med 26:1245-1252.
109. Zhao K, Luo G, Giannelli S, Szeto HH. 2005. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol 70:1796-1806.
110. Zhao K, Luo G, Zhao G-M, Schiller PW, Szeto HH. 2003. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J Pharmacol Exp Ther 304:425-432.
111. Zhao K, Zhao G-M, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. 2004. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279:34682-34690.
112. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ. 2009. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res 83:213-225.